Descripción del proyecto
Una nueva vacuna universal contra los brotes de gripe estacional
La gripe estacional y otras infecciones por virus respiratorios de ARN afectan cada año a aproximadamente el 10 % de la población mundial. La vacunación profiláctica actual tiene una eficacia limitada y requiere modificaciones con cada temporada de la gripe o brote pandémico debido a la elevada tasa de mutación de las proteínas de la superficie del virus sobre las cuales actúan las vacunas actuales. La empresa biotecnológica de fase clínica OSIVAX tiene por objeto desarrollar nuevas vacunas para prevenir las infecciones por virus respiratorios durante varias temporadas o brotes. OSIVAX ha desarrollado OVX836, un candidato a vacuna universal de la gripe basado en una tecnología privada de refuerzo inmunitario que desencadena respuestas inmunitarias dirigidas y duraderas. OVX836 evita la necesidad de volver a vacunarse contra la gripe al actuar sobre una proteína intravírica que conservan todas las cepas de la gripe. El objetivo del proyecto financiado con fondos europeos OSIRIX es preparar OVX836 para alcanzar el hito de la prueba de eficacia.
Objetivo
While an ongoing pandemic outbreak of coronavirus (COVID-19) is having enormous impact on global societies, a quest for effective vaccination becomes of unprecedented importance to save lives and economies globally.
Symptomatic flu, another respiratory RNA viral infection, affects ~10% of global population every year and leads to regular pandemic outbreaks. Existing prophylactic vaccination requires updates each flu season or pandemic outbreak, and has a strikingly limited efficacy (40% on average, as low as 9% in elderly). This is mainly due to a rapid mutation rate of surface viral proteins that are targeted by the current vaccines. Governments, institutions and vaccine community urgently seek for a universal flu vaccine that would provide a multi-season protection against all seasonal and emerging pandemic viral strains.
OSIVAX, a French clinical stage innovative biotech, strives to develop vaccines able to prevent respiratory viral infections across multiple seasons and outbreak. OSIVAX has developed OVX836, a best-in-class, game-changing universal flu vaccine candidate.
OVX836 is based on oligoDOM®, a proprietary immune-boosting technology that triggers powerful, targeted and durable immune responses involving activation of specific immune response killing infected cells. OVX836 circumvents the need for annual vaccination updates by targeting an intraviral protein that is highly conserved across all influenza strains.
OVX836 has a potential to disrupt the flu vaccine market currently dominated by single-season vaccines. The revolutionary universal flu vaccine is predicted to have a blockbuster potential (>€2.5 billion). OSIVAX’s experienced team aims to get OVX836 ready for the clinical proof-of-efficacy milestone (Phase IIb) that will position the company for >€500M licensing deal with a big pharma in 2024.
At the moment, OSIVAX leverages this revolutionary clinical-stage technology to initiate the development of a universal vaccine against corona
Ámbito científico
- medical and health sciencesbasic medicineimmunologyimmunisation
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenza
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-3
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
75008 Paris
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.